The development of pharmaceutical strategies in cardiovascular disease has been greatly aided by advancements in clinical trials and novel medication designs. Several cardiovascular medications have been found to provide cardiovascular benefits beyond the initial purpose for which they were developed. Statins are an excellent example of this, as they have been found to provide cardiovascular protection beyond their basic lipid lowering effects and are widely recommended for primary or secondary cardiovascular prevention, in addition to the lipid lowering effect. Similarly, in addition to their primary design as a blood pressure lowering pharmaceuticals, several types of antihypertensive medications have also been shown to reduce cardiovascular complications. However, the precise pleiotropic mechanisms by which certain cardiovascular therapeutics provide additional beneficial effects remains unknown. A better understanding of such mechanisms could allow the application and therapeutic potential of many common cardiovascular drugs to be maximized, and could aid in the development of further cardiovascular therapeutics.
Conversely, we may also observe several off-target, adverse cardiovascular side effects as a result of various cardiovascular and non-cardiovascular therapeutics. This has been observed in the use of certain ACE inhibitors, which may cause cardiac arrhythmias due to increased levels of potassium in the blood. This Research Topic has been developed with the aim of highlighting emerging research on the beneficial or adverse pleiotropic cardiovascular effects of drugs used in the treatment of cardiovascular or non-cardiovascular diseases.
We have organized this collection of articles within Frontiers in Cardiovascular Medicine, in order to collect original research, review, perspective, and opinion articles that share novel insights in the field of cardiovascular pleiotropism, cardiotoxicity and/or other side effects provided from pharmaceutical strategies.
Potential areas of research within this theme may include, but are not limited to:
1) The beneficial pleiotropic effects of cardiovascular therapeutics.
2) The precise mechanisms underlying the pleiotropic benefit of statins and other cardiovascular therapeutics.
3) Off-target benefits from cardiovascular or non-cardiovascular therapeutics on the vascular system.
4) Adverse cardiovascular effects of anti-hypertensive drugs.
5) Cardiovascular effects of non-steroidal anti-inflammatory drugs (NSAIDs).
6) Adverse cardiovascular effects of therapeutics used in the treatment of non-cardiovascular conditions, including but not limited to diabetes, and arthritis.
The development of pharmaceutical strategies in cardiovascular disease has been greatly aided by advancements in clinical trials and novel medication designs. Several cardiovascular medications have been found to provide cardiovascular benefits beyond the initial purpose for which they were developed. Statins are an excellent example of this, as they have been found to provide cardiovascular protection beyond their basic lipid lowering effects and are widely recommended for primary or secondary cardiovascular prevention, in addition to the lipid lowering effect. Similarly, in addition to their primary design as a blood pressure lowering pharmaceuticals, several types of antihypertensive medications have also been shown to reduce cardiovascular complications. However, the precise pleiotropic mechanisms by which certain cardiovascular therapeutics provide additional beneficial effects remains unknown. A better understanding of such mechanisms could allow the application and therapeutic potential of many common cardiovascular drugs to be maximized, and could aid in the development of further cardiovascular therapeutics.
Conversely, we may also observe several off-target, adverse cardiovascular side effects as a result of various cardiovascular and non-cardiovascular therapeutics. This has been observed in the use of certain ACE inhibitors, which may cause cardiac arrhythmias due to increased levels of potassium in the blood. This Research Topic has been developed with the aim of highlighting emerging research on the beneficial or adverse pleiotropic cardiovascular effects of drugs used in the treatment of cardiovascular or non-cardiovascular diseases.
We have organized this collection of articles within Frontiers in Cardiovascular Medicine, in order to collect original research, review, perspective, and opinion articles that share novel insights in the field of cardiovascular pleiotropism, cardiotoxicity and/or other side effects provided from pharmaceutical strategies.
Potential areas of research within this theme may include, but are not limited to:
1) The beneficial pleiotropic effects of cardiovascular therapeutics.
2) The precise mechanisms underlying the pleiotropic benefit of statins and other cardiovascular therapeutics.
3) Off-target benefits from cardiovascular or non-cardiovascular therapeutics on the vascular system.
4) Adverse cardiovascular effects of anti-hypertensive drugs.
5) Cardiovascular effects of non-steroidal anti-inflammatory drugs (NSAIDs).
6) Adverse cardiovascular effects of therapeutics used in the treatment of non-cardiovascular conditions, including but not limited to diabetes, and arthritis.
